RE: A further read ..30 Apr 2025 18:31
Anyone know if the BoD would be drip-fed data throughout the extended tox trials or will it come in one lump at the end? I know they stated 16wks plus a month or two to review the data but IF they're drip-fed during the study they may be in a position to give interested parties a sneek peek in the hope one blinks first.
As for our potential central nervous system molecules, I've just been reading the latest New Scientist article on Parkinson's Disease and there is evidence that there are two types - a brain-first and a body-first disease. The article notes, "...only a handful of medical centres around the world have the scanning equipment needed to differentiate between body-first or brain-first forms of the disease. However, future studies could divide trial participants into these two groups, so drugs are tested on those who have the best shot of benefiting from them. This could be particularly important when targeting the gut microbiome, which can be dramatically altered in people with Parkinson’s disease."
and
"In a study published in 2020, neurologist Haydeh Payami at the University of Alabama at Birmingham examined the gut microbiomes of 490 people with Parkinson’s and 234 people without the condition. She found that 30 per cent of the species of gut microorganisms in people with Parkinson’s were either abnormally elevated or depleted, compared
with those without the condition. One species that was elevated was Escherichia coli; some kinds of E. coli have been found to induce alpha-synuclein misfolding in the gut. Some bacteria can also stimulate inflammation, which could damage dopamine-producing neurons in the gut..."
I think the upshot there is that Parkinson's, like many diseases, isn't a one-drug-will-treat-it-all type of thing so I imagine the BoD will be aware of such pitfalls if they elected to target Parkinson's with our new molecule ahead of, say, MS.
I've read a great deal about quantum physics over the years and still find it perplexing but it's a doddle compared to medicine.
Sign In
Follow the stocks
